Buzzi M G, Dimitriadou V, Theoharides T C, Moskowitz M A
Department of Neurosurgery, Massachusetts General Hospital, Boston 02114.
Brain Res. 1992 Jun 26;583(1-2):137-49. doi: 10.1016/s0006-8993(10)80017-4.
Antidromic stimulation of small caliber trigeminal axons causes neurogenic inflammation in the dura mater and tongue as evidenced by marked increases in mast cell activation, protein extravasation, as well as in the numbers of endothelial cytoplasmic vesicles, endothelial microvilli and platelet aggregates within ipsilateral post-capillary venules. In this report, we examined the effects of pretreatment with serotonin1 receptor agonists, dihydroergotamine (50 micrograms/kg, i.v.) and sumatriptan (100 micrograms/kg, i.v.) on the light and electron microscopic changes which develop after trigeminal ganglion stimulation. Both dihydroergotamine and sumatriptan are useful in the acute treatment of vascular headaches and bind with high affinity to 5-HT1D receptors. Both drugs decreased significantly the number of dural vessels showing endothelial or platelet changes and the numbers of activated mast cells, but did not affect the neurogenic response in the tongue. The drugs also blocked the accumulation of horseradish peroxidase reaction product within the endothelium and perivascular space on the stimulated side. The receptor is not present on trigeminovascular fibers innervating extracranial cephalic tissues. Drug mechanism probably involves inhibition of a proximal step in the pathophysiological cascade (e.g., via activation of a prejunctional receptor) because (a) receptors for sumatriptan have not been identified on mast cells whereas the inflammatory response was attenuated in mast cells as well as within platelets and the endothelium and (b) previous work indicates that sumatriptan and dihydroergotamine block neurotransmitter release. Hence, constriction of vascular smooth muscle mediated by postjunctional 5-hydroxytryptamine receptors is unlikely to explain the anti-inflammatory actions of dihydroergotamine or sumatriptan reported here.
对小口径三叉神经轴突进行逆向刺激会导致硬脑膜和舌部发生神经源性炎症,表现为肥大细胞活化、蛋白外渗显著增加,同侧毛细血管后微静脉内的内皮细胞质小泡、内皮微绒毛和血小板聚集体数量也明显增多。在本报告中,我们研究了用5-羟色胺1受体激动剂二氢麦角胺(50微克/千克,静脉注射)和舒马曲坦(100微克/千克,静脉注射)预处理对三叉神经节刺激后出现的光镜和电镜变化的影响。二氢麦角胺和舒马曲坦在血管性头痛的急性治疗中均有效,且与5-HT1D受体具有高亲和力。两种药物均显著减少了出现内皮或血小板变化的硬脑膜血管数量以及活化肥大细胞的数量,但未影响舌部的神经源性反应。这两种药物还阻断了辣根过氧化物酶反应产物在受刺激侧内皮和血管周围间隙的积聚。支配颅外头颈部组织的三叉神经血管纤维上不存在该受体。药物作用机制可能涉及抑制病理生理级联反应中的近端步骤(例如,通过激活突触前受体),因为(a)在肥大细胞上尚未鉴定出舒马曲坦的受体,而肥大细胞以及血小板和内皮细胞内的炎症反应均减弱,且(b)先前的研究表明舒马曲坦和二氢麦角胺可阻断神经递质释放。因此,由突触后5-羟色胺受体介导的血管平滑肌收缩不太可能解释此处报道的二氢麦角胺或舒马曲坦的抗炎作用。